2011 was a big year for drugmakers seeking to get their innovative products approved, as the FDA blessed 30 new drugs, a 7-year high. Among the lucky ones were Johnson & Johnson ($JNJ) and GlaxoSmithKline ($GSK), both of which snagged three approvals each. Report